- Home
- RIV vs ITOS Comparison
RIV vs ITOS Comparison
Compare RIV & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- ITOS
- Stock Information
- Founded
- RIV 2015
- ITOS 2011
- Country
- RIV United States
- ITOS United States
- Employees
- RIV N/A
- ITOS N/A
- Industry
- RIV Finance Companies
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RIV Finance
- ITOS Health Care
- Exchange
- RIV Nasdaq
- ITOS Nasdaq
- Market Cap
- RIV 235.3M
- ITOS 270.7M
- IPO Year
- RIV N/A
- ITOS 2020
- Fundamental
- Price
- RIV $12.12
- ITOS $9.95
- Analyst Decision
- RIV
- ITOS Hold
- Analyst Count
- RIV 0
- ITOS 6
- Target Price
- RIV N/A
- ITOS $10.60
- AVG Volume (30 Days)
- RIV 87.6K
- ITOS 2.6M
- Earning Date
- RIV 01-01-0001
- ITOS 04-28-2025
- Dividend Yield
- RIV 12.85%
- ITOS N/A
- EPS Growth
- RIV N/A
- ITOS N/A
- EPS
- RIV N/A
- ITOS N/A
- Revenue
- RIV N/A
- ITOS $35,000,000.00
- Revenue This Year
- RIV N/A
- ITOS N/A
- Revenue Next Year
- RIV N/A
- ITOS $31.74
- P/E Ratio
- RIV N/A
- ITOS N/A
- Revenue Growth
- RIV N/A
- ITOS 177.89
- 52 Week Low
- RIV $9.63
- ITOS $4.80
- 52 Week High
- RIV $12.43
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- RIV 62.84
- ITOS 73.23
- Support Level
- RIV $11.92
- ITOS $9.85
- Resistance Level
- RIV $12.06
- ITOS $11.35
- Average True Range (ATR)
- RIV 0.14
- ITOS 0.52
- MACD
- RIV -0.00
- ITOS 0.20
- Stochastic Oscillator
- RIV 59.60
- ITOS 66.29
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.